T. Pressler

911 total citations
28 papers, 614 citations indexed

About

T. Pressler is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology. According to data from OpenAlex, T. Pressler has authored 28 papers receiving a total of 614 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 7 papers in Epidemiology and 3 papers in Molecular Biology. Recurrent topics in T. Pressler's work include Cystic Fibrosis Research Advances (21 papers), Tracheal and airway disorders (7 papers) and Pneumonia and Respiratory Infections (4 papers). T. Pressler is often cited by papers focused on Cystic Fibrosis Research Advances (21 papers), Tracheal and airway disorders (7 papers) and Pneumonia and Respiratory Infections (4 papers). T. Pressler collaborates with scholars based in Denmark, United Kingdom and Germany. T. Pressler's co-authors include Niels Høiby, Helle Krogh Johansen, Marianne Skov, Kasper Aanæs, C.R. Hansen, Svend Stenvang Pedersen, Claus Moser, Mikael Thastum, Peter Østrup Jensen and Mette Kolpen and has published in prestigious journals such as PLoS ONE, Journal of Antimicrobial Chemotherapy and Acta Paediatrica.

In The Last Decade

T. Pressler

26 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Pressler Denmark 13 406 179 86 76 62 28 614
Tim Lee United Kingdom 6 595 1.5× 149 0.8× 73 0.8× 140 1.8× 25 0.4× 7 683
Simon C Langton Hewer United Kingdom 10 389 1.0× 122 0.7× 82 1.0× 101 1.3× 61 1.0× 23 531
A Equi United Kingdom 6 421 1.0× 92 0.5× 56 0.7× 176 2.3× 29 0.5× 7 541
Jill M. Van Dalfsen United States 7 691 1.7× 160 0.9× 85 1.0× 129 1.7× 17 0.3× 8 819
Anne Prévötat France 11 626 1.5× 198 1.1× 15 0.2× 154 2.0× 52 0.8× 25 853
Hans‐Georg Posselt Germany 14 463 1.1× 102 0.6× 39 0.5× 141 1.9× 176 2.8× 38 808
Lisa A. Moulton United States 7 387 1.0× 352 2.0× 15 0.2× 82 1.1× 36 0.6× 8 626
A. Sewall United States 4 548 1.3× 90 0.5× 40 0.5× 103 1.4× 59 1.0× 5 643
Mark Dovey United States 11 644 1.6× 184 1.0× 50 0.6× 145 1.9× 26 0.4× 13 874
Sachinkumar B. Singh United States 12 284 0.7× 97 0.5× 26 0.3× 45 0.6× 22 0.4× 26 410

Countries citing papers authored by T. Pressler

Since Specialization
Citations

This map shows the geographic impact of T. Pressler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Pressler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Pressler more than expected).

Fields of papers citing papers by T. Pressler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Pressler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Pressler. The network helps show where T. Pressler may publish in the future.

Co-authorship network of co-authors of T. Pressler

This figure shows the co-authorship network connecting the top 25 collaborators of T. Pressler. A scholar is included among the top collaborators of T. Pressler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Pressler. T. Pressler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taccetti, Giovanni, M. Denton, Diana Bilton, et al.. (2019). A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials. Journal of Cystic Fibrosis. 19(1). 52–67. 8 indexed citations
2.
Flume, Patrick A., Gregory S. Sawicki, T. Pressler, et al.. (2018). WS01.2 Phase 2 initial results evaluating PTI-428, a novel CFTR amplifier, in patients with cystic fibrosis. Journal of Cystic Fibrosis. 17. S1–S2. 8 indexed citations
3.
4.
Pressler, T., Scott H. Donaldson, Knut T. Smerud, & Astrid Hilde Myrset. (2017). WS01.3 A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis. Journal of Cystic Fibrosis. 16. S1–S2. 3 indexed citations
5.
Alanin, Mikkel Christian, Kasper Aanæs, Niels Høiby, et al.. (2016). Sinus surgery postpones chronic Gram-negative lung infection: cohort study of 106 patients with cystic fibrosis. Rhinology Journal. 54(3). 206–213. 25 indexed citations
6.
Pressler, T., et al.. (2016). COACH TO COPE: FEASIBILITY OF A COACHING INTERVENTION FOR YOUNG ADULTS WITH CYSTIC FIBROSIS. Research at the University of Copenhagen (University of Copenhagen). 51. 464–465. 2 indexed citations
7.
Kolpen, Mette, Michael Kühl, Thomas Bjarnsholt, et al.. (2014). Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Lung Infection. PLoS ONE. 9(1). e84353–e84353. 73 indexed citations
8.
Stern, Martin, Dominique Bertrand, Elisabetta Bignamini, et al.. (2014). European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. Journal of Cystic Fibrosis. 13. S43–S59. 34 indexed citations
9.
Alanin, Mikkel Christian, Helle Krogh Johansen, Kasper Aanæs, et al.. (2014). Simultaneous sinus and lung infections in patients with primary ciliary dyskinesia. Acta Oto-Laryngologica. 135(1). 58–63. 30 indexed citations
10.
Taylor‐Robinson, David, et al.. (2013). Author's response: Understanding the natural progression in %FEV decline in patients with cystic fibrosis: A longitudinal study. UCL Discovery (University College London).
11.
Hansen, C.R., et al.. (2011). Chronic pulmonary infection with Stenotrophomonas maltophilia and lung function in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(5). 318–325. 46 indexed citations
12.
Boisen, Kirsten A., et al.. (2011). Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents. Patient Preference and Adherence. 5. 507–507. 71 indexed citations
13.
14.
Fluge, G, Hanne Vebert Olesen, Marita Gilljam, et al.. (2009). Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. Journal of Cystic Fibrosis. 8(3). 198–202. 45 indexed citations
15.
Hansen, C.R., et al.. (2009). Chronic infection with Achromobacter xylosoxidans leads to rapid decrease towards end-stage lung disease in cystic fibrosis patients. Journal of Cystic Fibrosis. 8. S64–S64. 2 indexed citations
16.
Pressler, T.. (2008). Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis. Biologics. 2(4). 611–611. 38 indexed citations
17.
Lindblad, Anders, et al.. (2008). Linoleic acid but not EPA and DHA correlates to prognostic markers in Scandinavian CF patients. Journal of Cystic Fibrosis. 7. S93–S93. 4 indexed citations
18.
Bergan, Tom, et al.. (1993). Pharmacokinetic Evaluation of Imipenem Combined with Cilastatin in Cystic Fibrosis. Chemotherapy. 39(6). 369–373. 8 indexed citations
19.
Pedersen, Svend Stenvang, Tim Jensen, T. Pressler, Niels Høiby, & Kirsten Rosendal. (1986). Does Centralized Treatment of Cystic Fibrosis Increase the Risk of Pseudomonas aeruginosa Infection?. Acta Paediatrica. 75(5). 840–845. 36 indexed citations
20.
Pedersen, Svend Stenvang, T. Pressler, Mogens Theisen Pedersen, et al.. (1986). Immediate and Prolonged Clinical Efficacy of Ceftazidime versus Ceftazidime plus Tobramycin in Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Scandinavian Journal of Infectious Diseases. 18(2). 133–137. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Lee Breakdown of academic impact, for papers by Simon C Langton Hewer Breakdown of academic impact, for papers by A Equi Breakdown of academic impact, for papers by Jill M. Van Dalfsen Breakdown of academic impact, for papers by Anne Prévötat Breakdown of academic impact, for papers by Hans‐Georg Posselt Breakdown of academic impact, for papers by Lisa A. Moulton Breakdown of academic impact, for papers by A. Sewall Breakdown of academic impact, for papers by Mark Dovey Breakdown of academic impact, for papers by Sachinkumar B. Singh
Rankless by CCL
2026